Quick Answer
LianBio reported R&D Expense of $59.76 million for fiscal year 2022.
LianBio R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2022 | $59.76M | -62.3% |
| 2021 | $158.69M | +31.3% |
| 2020 | $120.89M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2023 | $9.02M | +9.2% | -4.6% |
| June 30, 2023 | $9.45M | -66.9% | -12.7% |
| March 31, 2023 | $10.83M | -12.2% | +31.2% |
| September 30, 2022 | $8.26M | +77.4% | -71.1% |
| June 30, 2022 | $28.59M | -69.3% | +131.9% |
| March 31, 2022 | $12.33M | -76.9% | +164.9% |
| September 30, 2021 | $4.66M | — | -95.0% |
| June 30, 2021 | $93.03M | — | +74.4% |
- LianBio showed a decrease of -62.3% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2022 period, LianBio’s r&d expense has declined by 50.6% (from $120.89 million to $59.76 million).
- The most recent figure is from LianBio’s fiscal year 2022 report (Form 10-K), filed with the SEC on March 28, 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: